Log in

Relevant bibliographies by topics / Exogenous surfactant therapy / Journal articles

To see the other types of publications on this topic, follow the link: Exogenous surfactant therapy.

Journal articles on the topic 'Exogenous surfactant therapy'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Exogenous surfactant therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Suresh, G. K., and R. F. Soll. "Exogenous Surfactant Therapy in Newborn Infants." Annals of the Academy of Medicine, Singapore 32, no. 3 (2003): 335–45. http://dx.doi.org/10.47102/annals-acadmedsg.v32n3p335.

Full text

Abstract:

Exogenous surfactant therapy has an established role in the management of neonatal respiratory distress syndrome (RDS). This article summarises the current evidence on surfactant therapy. The use of surfactant for the treatment or prophylaxis of neonatal RDS results in a 30% to 65% relative reduction in the risk of pneumothorax and up to a 40% relative reduction in the risk of mortality. Adverse effects, of which pulmonary haemorrhage is of most concern, are infrequent and long-term follow-up studies of treated patients are reassuring. Natural surfactants have advantages over synthetic surfact

APA, Harvard, Vancouver, ISO, and other styles

2

Dipak, Kumar Dhar, and Paul Debasish. "Surfactant Replacement Therapy: An Overview." International Journal of Science and Healthcare Research 5, no. 2 (2020): 399–406. https://doi.org/10.5281/zenodo.3931623.

Full text

Abstract:

Pulmonary surfactant is a soap-like chemical synthesized by type II alveolar pneumocytes and is a mixture of phospholipids (predominantly dipalmitoylphosphatidylcholine), some other lipids and proteins. Its main functions include lowering the surface tension and maintaining the stability of alveoli. The first documented trial involving exogenous use of surfactants as a therapy was recorded in early 1970s using synthetically produced phospholipid mixtures once the chemical composition of surfactants was deciphered. Gradually there was a transition to the use of more natural sources. And animal

APA, Harvard, Vancouver, ISO, and other styles

3

Merritt, T. Allen, and Henry L. Halliday. "On exogenous surfactant therapy." Pediatric Pulmonology 14, no. 1 (1992): 1–3. http://dx.doi.org/10.1002/ppul.1950140102.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Grotberg, J. B., D. Halpern, and O. E. Jensen. "Interaction of exogenous and endogenous surfactant: spreading-rate effects." Journal of Applied Physiology 78, no. 2 (1995): 750–56. http://dx.doi.org/10.1152/jappl.1995.78.2.750.

Full text

Abstract:

The spreading rate of an exogenous surfactant monolayer due to surface tension gradients is examined by using our previously reported theoretical analysis, with particular attention given to the effects of endogenous surfactant. It is found that the presence of an endogenous surfactant reduces the spreading rate of exogenous surfactant and that, in certain circumstances, the spreading may be halted. A recently published paper (F. F. Espinosa, A. H. Shapiro, J. J. Fredberg, and R. D. Kamm. J. Appl. Physiol. 75: 2028–2039, 1993) reaches the opposite conclusion about the effect of endogenous surf

APA, Harvard, Vancouver, ISO, and other styles

5

Freddi, Norberto A., José Oliva Proença Filho, and Humberto H. Fiori. "Exogenous surfactant therapy in pediatrics." Jornal de Pediatria 79, no. 8 (2003): 205–12. http://dx.doi.org/10.2223/jped.1097.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Maruscak, Adam, and Jim F. Lewis. "Exogenous surfactant therapy for ARDS." Expert Opinion on Investigational Drugs 15, no. 1 (2005): 47–58. http://dx.doi.org/10.1517/13543784.15.1.47.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Lacaze-Masmonteil, Thierry. "Exogenous surfactant therapy: newer developments." Seminars in Neonatology 8, no. 6 (2003): 433–40. http://dx.doi.org/10.1016/s1084-2756(03)00120-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Froese, Alison B. "Exogenous Surfactant Therapy in ARDS." Chest 105, no. 5 (1994): 1310–12. http://dx.doi.org/10.1378/chest.105.5.1310.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Ramanathan, Rangasamy. "Surfactants in the Management of Respiratory Distress Syndrome in Extremely Premature Infants." Journal of Pediatric Pharmacology and Therapeutics 11, no. 3 (2006): 132–44. http://dx.doi.org/10.5863/1551-6776-11.3.132.

Full text

Abstract:

Respiratory distress syndrome (RDS) is primarily due to decreased production of pulmonary surfactant, and it is associated with significant neonatal morbidity and mortality. Exogenous pulmonary surfactant therapy is currently the treatment of choice for RDS, as it demonstrates the best clinical and economic outcomes. Studies confirm the benefits of surfactant therapy to include reductions in mortality, pneumothorax, and pulmonary interstitial emphysema, as well as improvements in oxygenation and an increased rate of survival without bronchopulmonary dysplasia. Phospholipids (PL) and surfactant

APA, Harvard, Vancouver, ISO, and other styles

10

Willson, D. F., and R. H. Notter. "The Future of Exogenous Surfactant Therapy." Respiratory Care 56, no. 9 (2011): 1369–88. http://dx.doi.org/10.4187/respcare.01306.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Boeckling, Annette Carley. "Exogenous surfactant therapy for premature infants." Journal of Perinatal & Neonatal Nursing 6, no. 2 (1992): 59–66. http://dx.doi.org/10.1097/00005237-199209000-00007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Merritt, T. Allen, Roger F. Soll, and Mikko Hallman. "Overview of Exogenous Surfactant Replacement Therapy." Journal of Intensive Care Medicine 8, no. 5 (1993): 205–28. http://dx.doi.org/10.1177/088506669300800501.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Novikov, N. Y., A. L. Potapov, and A. V. Boiarkina. "Exogenous Surfactant Therapy Affects Short-Term Survival in Patients With Acute Respiratory Distress Syndrome: Retrospective Analysis of 137 Fatal Cases." Journal of Health Sciences 4, no. 14 (2014): 121–26. https://doi.org/10.5281/zenodo.13329.

Full text

Abstract:

<strong>Novikov N. Y., Potapov A. L., Boiarkina A. V. Exogenous Surfactant Therapy Affects Short-Term Survival in Patients With Acute Respiratory Distress Syndrome: Retrospective Analysis of 137 Fatal Cases</strong><strong>. </strong><strong>Journal of Health Sciences. 2014;4(14):121-126. ISSN 1429-9623 / 2300-665X.</strong> <strong>http://ojs.ukw.edu.pl/index.php/johs/article/view/2014%3B4%2814%29%3A121-126</strong> <strong>http://journal.rsw.edu.pl/index.php/JHS/article/view/2014%3B4%2814%29%3A121-126</strong> <strong>https://pbn.nauka.gov.pl/works/512346</strong> <strong>DOI: </strong><stro

APA, Harvard, Vancouver, ISO, and other styles

14

Lewis, James F., Jasvinder S. Dhillon, Ram N. Singh, Craig C. Johnson, and Timothy C. Frewen. "Exogenous Surfactant Therapy for Pediatric Patients with Acute Respiratory Distress Syndrome." Canadian Respiratory Journal 4, no. 1 (1997): 21–26. http://dx.doi.org/10.1155/1997/903459.

Full text

Abstract:

Exogenous surfactant administration is currently being tested in patients with the acute respiratory distress syndrome (ARDS). The results of the studies have varied because several factors may influence the host’s response to this therapy. This clinical pilot study was designed to evaluate the safety and efficacy of exogenous surfactant administration in pediatric patients with ARDS. Surfactant was administered to 13 patients with severe lung dysfunction, and eight of these patients experienced a significant improvement in oxygenation after the first dose of surfactant. In these patients the

APA, Harvard, Vancouver, ISO, and other styles

15

Ruaro, Barbara, Paola Confalonieri, Riccardo Pozzan, et al. "Severe COVID-19 ARDS Treated by Bronchoalveolar Lavage with Diluted Exogenous Pulmonary Surfactant as Salvage Therapy: In Pursuit of the Holy Grail?" Journal of Clinical Medicine 11, no. 13 (2022): 3577. http://dx.doi.org/10.3390/jcm11133577.

Full text

Abstract:

Background: Severe pneumonia caused by coronavirus disease 2019 (COVID-19) is characterized by inflammatory lung injury, progressive parenchymal stiffening and consolidation, alveolar and airway collapse, altered vascular permeability, diffuse alveolar damage, and surfactant deficiency. COVID-19 causes both pneumonia and acute respiratory distress syndrome (COVID-19 ARDS). COVID-19 ARDS is characterized by severe refractory hypoxemia and high mortality. Despite extensive research, the treatment of COVID-19 ARDS is far from satisfactory. Some treatments are recommended for exhibiting some clini

APA, Harvard, Vancouver, ISO, and other styles

16

Verbrugge, S. J. C., D. Gommers, and B. Lachmann. "First clinical experiences with exogenous surfactant therapy." Intensivmedizin und Notfallmedizin 36, S1 (1999): S070—S074. http://dx.doi.org/10.1007/pl00014614.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Puligandla, Pramod S., Tara Gill, Lynda A. McCaig, et al. "Alveolar environment influences the metabolic and biophysical properties of exogenous surfactants." Journal of Applied Physiology 88, no. 3 (2000): 1061–71. http://dx.doi.org/10.1152/jappl.2000.88.3.1061.

Full text

Abstract:

Several factors have been shown to influence the efficacy of exogenous surfactant therapy in the acute respiratory distress syndrome. We investigated the effects of four different alveolar environments (control, saline-lavaged, N-nitroso- N-methylurethane, and hydrochloric acid) on the metabolic and functional properties of two exogenous surfactant preparations: bovine lipid extract surfactant and recombinant surfactant-associated protein (SP) C drug product (rSPC) administered to each of these groups. The main difference between these preparations was the lack of SP-B in the rSPC. Our results

APA, Harvard, Vancouver, ISO, and other styles

18

Rahaman, Sk Mehebub, Budhadeb Chowdhury, Animesh Acharjee, Bula Singh, and Bidyut Saha. "Surfactant-based therapy against COVID-19: A review." Tenside Surfactants Detergents 58, no. 6 (2021): 410–15. http://dx.doi.org/10.1515/tsd-2021-2382.

Full text

Abstract:

Abstract The coronavirus disease 2019 (COVID-19) has led to serious health and economic damage to all over the world, and it still remains unstoppable. The SARS-CoV-2, by using its S-glycoprotein, binds with an angiotensin-converting enzyme 2 receptor, mostly present in alveolar epithelial type II cells. Eventually pulmonary surfactant depletion occurs. The pulmonary surfactant is necessary for maintaining the natural immunity as well as the surface tension reduction within the lung alveoli during the expiration. Its insufficiency results in the reduction of blood oxygenation, poor pulmonary r

APA, Harvard, Vancouver, ISO, and other styles

19

Erokhin, V. V., L. N. Lepekha, M. V. Erokhina, I. V. Bocharova, A. V. Kurynina, and G. E. Onishchenko. "SELECTIVE EFFECTS OF PULMONARY SURFACTANT ON VARIOUS SUBPOPULATIONS OF ALVEOLAR MACROPHAGES IN THE MODEL OF EXPERIMENTAL TUBERCULOSIS." Annals of the Russian academy of medical sciences 67, no. 11 (2012): 22–28. http://dx.doi.org/10.15690/vramn.v67i11.467.

Full text

Abstract:

Pulmonary surfactant is necessary component for maintenance of high level of phagocytic activity of alveolar macrophages. Tuberculosis inflammation reduces the production of surfactant by type II cells and phagocytic activity of alveolar macrophages. The effects of exogenous pulmonary surfactant on the ultrastructural changes of various subpopulations of alveolar macrophages were studied by TEM-method. For investigations the bronchial alveolar lavage fluid from guinea pigs infected of M. tuberculosis and treated by isoniazid or isoniazid + exogenous pulmonary surfactant were used. It was shown

APA, Harvard, Vancouver, ISO, and other styles

20

Antonova, Nadia, Roumen Todorov, and Dotchi Exerowa. "Rheological behavior and parameters of the in vitro model of lung surfactant systems: The role of the main phospholipid component." Biorheology: The Official Journal of the International Society of Biorheology 40, no. 5 (2003): 531–43. http://dx.doi.org/10.1177/0006355x2003040005006.

Full text

Abstract:

The proposed in vitro model for studying the alveolar surface layer of the lungs enables one to investigate the surface intermolecular forces which influence the stability of the alveolus. The general role for the stability of the alveolus belongs to the phospholipids in the alveolar surfactant and predominantly to their main component dipalmitoylphosphatidylcholine (DPPC). The aim of the study was to investigate the rheological behavior of DPPC and exogenous surfactant preparations used in neonatal clinical practice. Data for the rheological behavior of the solutions of the commercially avail

APA, Harvard, Vancouver, ISO, and other styles

21

Vidyasagar, Dharmapuri, Haruo Maeta, Tonse N. Raju, et al. "EXOGENOUS SURFACTANT THERAPY IN BABOON HYALINE MEMBRANE DISEASE." Critical Care Medicine 14, no. 4 (1986): 360. http://dx.doi.org/10.1097/00003246-198604000-00099.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Raju, Tonse N. K., and Patricia Langenberg. "Pulmonary hemorrhage and exogenous surfactant therapy: A metaanalysis." Journal of Pediatrics 123, no. 4 (1993): 603–10. http://dx.doi.org/10.1016/s0022-3476(05)80963-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Lawson, Edward E. "Exogenous surfactant therapy to prevent respiratory distress syndrome." Journal of Pediatrics 110, no. 3 (1987): 492–93. http://dx.doi.org/10.1016/s0022-3476(87)80524-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Greenough, A. "Neonatal chronic lung disease and exogenous surfactant therapy." European Journal of Pediatrics 157, S1 (1998): S16—S18. http://dx.doi.org/10.1007/pl00014283.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Silva, Johnatas Dutra, Gisele Pena de Oliveira, Cynthia dos Santos Samary, et al. "Respiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome." Cellular Physiology and Biochemistry 38, no. 2 (2016): 821–35. http://dx.doi.org/10.1159/000443037.

Full text

Abstract:

Background/Aims: Exogenous surfactant has been proposed as adjunctive therapy for acute respiratory distress syndrome (ARDS), but it is inactivated by different factors present in the alveolar space. We hypothesized that co-administration of LASSBio596, a molecule with significant anti-inflammatory properties, and exogenous surfactant could reduce lung inflammation, thus enabling the surfactant to reduce edema and improve lung function, in experimental ARDS. Methods: ARDS was induced by cecal ligation and puncture surgery in BALB/c mice. A sham-operated group was used as control (CTRL). After

APA, Harvard, Vancouver, ISO, and other styles

26

Gitlin, Jonathan D., Roger F. Soll, Richard B. Parad, et al. "Randomized Controlled Trial of Exogenous Surfactant for the Treatment of Hyaline Membrane Disease." Pediatrics 79, no. 1 (1987): 31–37. http://dx.doi.org/10.1542/peds.79.1.31.

Full text

Abstract:

We conducted a prospective, randomized, unblinded, controlled trial of exogenous bovine surfactant (surfactant TA) in premature infants requiring ventilator support for the treatment of severe hyaline membrane disease. Forty-one low birth weight infants with severe hyaline membrane disease were randomly assigned to saline or surfactant therapy and treated within eight hours of birth. Significant improvements in oxygenation (increased arterial/alveolar Po2) and respiratory support (decreased mean airway pressure) were seen in the group receiving surfactant within four hours after treatment. The

APA, Harvard, Vancouver, ISO, and other styles

27

Satyam Prakash, Hem Shankar Yadav, and Om Prakash Yadav. "Pulmonary Surfactant in Health and Disease: An Overview." Janaki Medical College Journal of Medical Science 12, no. 03 (2024): 108–22. https://doi.org/10.3126/jmcjms.v12i03.73990.

Full text

Abstract:

Surfactant is a complex mixture of phospholipids, mainly dipalmitoylphosphatidylcholine (DPCC) and surfactant proteins (SP); SP-A, SP-B, SP-C, and SP-D. DPCC plays a crucial role in lowering the surface tension, while SPs provide immunity against invading pathogens. SPs also enhance the activity of phospholipids, aiding in the adsorption and spread of surfactants all over the alveolar surface. Surfactant production starts as early as 24 weeks of gestation in humans and peaks at about 36-38 weeks. The generation and secretion of lung surfactants are tightly regulated processes. Surfactant is sy

APA, Harvard, Vancouver, ISO, and other styles

28

Aspros, Alexander J., Claudia G. Coto, James F. Lewis, and Ruud A. W. Veldhuizen. "High-frequency oscillation and surfactant treatment in an acid aspiration model." Canadian Journal of Physiology and Pharmacology 88, no. 1 (2010): 14–20. http://dx.doi.org/10.1139/y09-096.

Full text

Abstract:

Both exogenous surfactant therapy and high-frequency oscillation (HFO) have been proposed as clinical interventions in acute respiratory distress syndrome (ARDS). The combination of these 2 interventions has not been studied in a relevant model of ARDS. It was hypothesized that surfactant treatment combined with HFO is superior to either surfactant treatment or HFO alone in a model of ARDS. Adult rats had lung injury induced by instillation of 0.1 mol/L HCl, followed by randomization to one of 4 groups: Conventional mechanical ventilation (CMV) + air (no treatment), CMV + surfactant, HFO + air

APA, Harvard, Vancouver, ISO, and other styles

29

Birkun, Alexei. "Exogenous Pulmonary Surfactant as a Vehicle for Antimicrobials: Assessment of Surfactant-Antibacterial InteractionsIn Vitro." Scientifica 2014 (2014): 1–6. http://dx.doi.org/10.1155/2014/930318.

Full text

Abstract:

Owing to its unique surface-active properties, an exogenous pulmonary surfactant may become a promising drug delivery agent, in particular, acting as a vehicle for antibiotics in topical treatment of pneumonia. The purpose of this study was to assess a mutual influence of natural surfactant preparation and three antibiotics (amikacin, cefepime, and colistimethate sodium)in vitroand to identify appropriate combination(s) for subsequentin vivoinvestigations of experimental surfactant/antibiotic mixtures. Influence of antibiotics on surface-active properties of exogenous surfactant was assessed u

APA, Harvard, Vancouver, ISO, and other styles

30

Moreno, M., J. López-Herce, C. Merello, A. Alcaraz, and A. Carrillo. "Exogenous surfactant therapy for acute respiratory distress in infancy." Intensive Care Medicine 22, no. 1 (1996): 87. http://dx.doi.org/10.1007/bf01728337.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Amin, Tahsinul, and Mohammod Shahidullah. "Surfactant Replacement Therapy for Respiratory Distress Syndrome in the Newborn: A Review." Bangladesh Journal of Child Health 40, no. 1 (2017): 26–30. http://dx.doi.org/10.3329/bjch.v40i1.31552.

Full text

Abstract:

Respiratory failure secondary to surfactant deficiency is a major cause of morbidity and mortality in low birth weight premature infants. Surfactant therapy substantially reduces mortality and respiratory morbidity for this population. Exogenous surfactant therapy has become well established in newborn infants with respiratory distress. Many aspects of its use have been well evaluated in high-quality trials and systematic reviews. Secondary surfactant deficiency also contributes to acute respiratory morbidity in late-preterm and term neonates with meconium aspiration syndrome, pneumonia/ sepsi

APA, Harvard, Vancouver, ISO, and other styles

32

Pandit, Paresh B., Michael S. Dunn, and Enza A. Colucci. "Surfactant Therapy In Neonates With Respiratory Deterioration Due to Pulmonary Hemorrhage." Pediatrics 95, no. 1 (1995): 32–36. http://dx.doi.org/10.1542/peds.95.1.32.

Full text

Abstract:

Objective. To study the effect of exogenous bovine surfactant on oxygen and ventilatory requirements in neonates with respiratory deterioration due to pulmonary hemorrhage. Design. Retrospective case series. Setting. Three regional neonatal intensive care units. Methods. Infants who received surfactant following a clinically significant pulmonary hemorrhage during the time period July 1991 to December 1993 were identified from a database. Infants were excluded if any other cause was found to explain their deterioration. The primary outcome was change in respiratory status following surfactant

APA, Harvard, Vancouver, ISO, and other styles

33

Espinosa, F. F., and R. D. Kamm. "Bolus dispersal through the lungs in surfactant replacement therapy." Journal of Applied Physiology 86, no. 1 (1999): 391–410. http://dx.doi.org/10.1152/jappl.1999.86.1.391.

Full text

Abstract:

A model is presented of surfactant replacement therapy. An instilled bolus is pushed into the lungs on the first inspiration, coating the airways with a layer of surfactant and depositing some in the alveoli. Layer thickness depends on the capillary number (μ U/γ, where μ, U, and γ are bolus viscosity, advancing meniscus velocity, and surface tension, respectively). Larger capillary number leads to thicker layers, reducing alveolar delivery. Subsequently, surface tension gradients sweep surfactant into alveoli not receiving surfactant during the first inspiration. The effects on spreading of s

APA, Harvard, Vancouver, ISO, and other styles

34

Tingay, David Gerald, Andrea Togo, Prue M. Pereira-Fantini, et al. "Aeration strategy at birth influences the physiological response to surfactant in preterm lambs." Archives of Disease in Childhood - Fetal and Neonatal Edition 104, no. 6 (2019): F587—F593. http://dx.doi.org/10.1136/archdischild-2018-316240.

Full text

Abstract:

BackgroundThe influence of pressure strategies to promote lung aeration at birth on the subsequent physiological response to exogenous surfactant therapy has not been investigated.ObjectivesTo compare the effect of sustained inflation (SI) and a dynamic positive end-expiratory pressure (PEEP) manoeuvre at birth on the subsequent physiological response to exogenous surfactant therapy in preterm lambs.MethodsSteroid-exposed preterm lambs (124–127 days’ gestation; n=71) were randomly assigned from birth to either (1) positive-pressure ventilation (PPV) with no recruitment manoeuvre; (2) SI until

APA, Harvard, Vancouver, ISO, and other styles

35

Voronkova, O. O., A. A. Starzhevskaia, V. G. Skachek, et al. "The use of inhaled tauractant therapy in the subacute period of COVID-19." Meditsinskiy sovet = Medical Council, no. 4 (April 13, 2023): 50–56. http://dx.doi.org/10.21518/ms2023-084.

Full text

Abstract:

The subacute period of coronavirus infection is a 4- to-12-week period after acute illness associated with the SARS-CoV-2 infection. A range of bronchopulmonary symptoms in the subacute period of COVID-19 includes cough, shortness of breath, reduced exercise tolerance, which, in turn, worsens the patient’s quality of life. Despite all the achievements of modern medicine, there is still no exact understanding of the mechanisms of this condition. There are also limitations of current patients’ treatments. The successful use of exogenous surfactant in the acute period of SARS-CoV-2 infection has

APA, Harvard, Vancouver, ISO, and other styles

36

Kari, M. A., T. Akino, and M. Hallman. "Prenatal Dexamethasone and Exogenous Surfactant Therapy: Surface Activity and Surfactant Components in Airway Specimens." Pediatric Research 38, no. 5 (1995): 676–84. http://dx.doi.org/10.1203/00006450-199511000-00008.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Shapovalov, K. G., S. А. Lukyanov, V. А. Konnov, and O. А. Rozenberg. "Exogenous surfactant in the late respiratory phase of COVID-19." Tuberculosis and Lung Diseases 99, no. 5 (2021): 7–13. http://dx.doi.org/10.21292/2075-1230-2021-99-5-7-13.

Full text

Abstract:

The article presents data on the course of inhalations with a native surfactant administered in two patients (66 and 53 years old) at the late respiratory phase of the new coronavirus infection of COVID-19 (the 22nd and the 19th days from the disease onset) who received non-invasive artificial lung ventilation.Subjects and methods. For inhalations, an AeroNeb™ micropump nebulizer was used; for one inhalation, 75 mg of surfactant-BL was dissolved in 5 ml of isotonic sodium chloride solution. The treatment course included 5 days with 2 inhalations a day.Results. In both patients, upon the end of

APA, Harvard, Vancouver, ISO, and other styles

38

Lewis, J. F., B. Tabor, M. Ikegami, A. H. Jobe, M. Joseph, and D. Absolom. "Lung function and surfactant distribution in saline-lavaged sheep given instilled vs. nebulized surfactant." Journal of Applied Physiology 74, no. 3 (1993): 1256–64. http://dx.doi.org/10.1152/jappl.1993.74.3.1256.

Full text

Abstract:

Adult sheep (35 +/- 3 kg) underwent saline lung lavage and 1.5 h of mechanical ventilation to induce acute lung injury. Animals received 100 mg lipid/kg body wt of tracheally instilled surfactant (Inst Surf) or either nebulized surfactant (Neb Surf) or nebulized saline (Neb Saline) and were killed 3 h later. Inst Surf and Neb Surf groups had significant improvements in oxygenation (P < 0.01) and peak inspiratory pressures (PIP) (P < 0.05) compared with pretreatment values. Improvements in oxygenation and PIP for Inst Surf animals were significantly greater than for Neb Surf animals (P &l

APA, Harvard, Vancouver, ISO, and other styles

39

Namgung, Ran, Chul Lee, Jin-Suk Suh, Kook-In Park, and Dong-Gwan Han. "Exogenous surfactant replacement therapy of hyaline membrane disease in premature infants." Yonsei Medical Journal 30, no. 4 (1989): 355. http://dx.doi.org/10.3349/ymj.1989.30.4.355.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Novick, Richard J., Andrea A. Gilpin, Kenneth E. Gehman, et al. "Mitigation of injury in canine lung grafts by exogenous surfactant therapy." Journal of Thoracic and Cardiovascular Surgery 113, no. 2 (1997): 342–53. http://dx.doi.org/10.1016/s0022-5223(97)70332-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

BANERJEE, R., and R. R. PUNIYANI. "Exogenous Surfactant Therapy and Mucus Rheology in Chronic Obstructive Airway Diseases." Journal of Biomaterials Applications 14, no. 3 (2000): 243–72. http://dx.doi.org/10.1106/9d4b-l6pp-7ctf-by8g.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Banerjee, R., and R. R. Puniyani. "Exogenous Surfactant Therapy and Mucus Rheology in Chronic Obstructive Airway Diseases." Journal of Biomaterials Applications 14, no. 3 (2000): 243–72. http://dx.doi.org/10.1177/088532820001400304.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Voronkova, O. O., N. A. Nikolaeva, G. B. Abdullaeva, O. E. Buyanova, E. F. Rogova, and Yu N. Belenkov. "The dynamics of respiratory changes on the background of inhalation treatment with tauractant in patients in the post-covid period." Meditsinskiy sovet = Medical Council, no. 9 (June 22, 2025): 91–96. https://doi.org/10.21518/ms2025-229.

Full text

Abstract:

Introduction. Pulmonary surfactant is a key component of the respiratory system that ensures the stability of the alveoli by reducing surface tension, preventing collapse of the respiratory tract and protecting against infections. Its dysfunction is observed in severe respiratory diseases, including COVID-19, ARDS, pneumonia, COPD and bronchial asthma. Of particular interest is the inhalation use of exogenous forms of surfactant not only in acute COVID-19, but also in the post-covid period.Aim. The aim of the study is to evaluate the effectiveness of a course of inhalation of tauractant emulsi

APA, Harvard, Vancouver, ISO, and other styles

44

Shvechkova, M. V., I. I. Kukarskaya, A. E. Bautin, et al. "Surfactant therapy for pneumonia COVID-19 of obstetric patients." Meditsinskiy sovet = Medical Council, no. 4 (April 6, 2022): 66–73. http://dx.doi.org/10.21518/2079-701x-2022-16-4-66-73.

Full text

Abstract:

Introduction. Pregnant women may be at increased risk for severe COVID-19 illness. Pregnant women are more likely to be hospitalized at ICU, needed the mechanical ventilation compared to nonpregnant women of childbearing age. Building on the experience of the effective use of the exogenous surfactant for influenza A/H1N1 treatment of pregnant women with COVID-19, the surfactant therapy has also been included in the treatment.The objective. To evaluate the effectiveness of surfactant therapy in the integrated treatment of severe COVID-19 pneumonia of pregnant women and postpartum women.Material

APA, Harvard, Vancouver, ISO, and other styles

45

McPherson, Christopher, and Jennifer A. Wambach. "Prevention and Treatment of Respiratory Distress Syndrome in Preterm Neonates." Neonatal Network 37, no. 3 (2018): 169–77. http://dx.doi.org/10.1891/0730-0832.37.3.169.

Full text

Abstract:

Respiratory distress syndrome (RDS) impacts a high proportion of preterm neonates, resulting in significant morbidity and mortality. Advances in pharmacotherapy, specifically antenatal corticosteroids and postnatal surfactant therapy, have significantly reduced the incidence and impact of neonatal RDS. Antenatal corticosteroids accelerate fetal lung maturation by increasing the activity of enzymes responsible for surfactant biosynthesis, resulting in improved lung compliance. Maternal antenatal corticosteroid treatment has improved survival of preterm neonates and lowered the incidence of brai

APA, Harvard, Vancouver, ISO, and other styles

46

Keshavarzi, Atoosa, Ali Asi Shirazi, Rastislav Korfanta, et al. "Thermodynamic and Structural Study of Budesonide—Exogenous Lung Surfactant System." International Journal of Molecular Sciences 25, no. 5 (2024): 2990. http://dx.doi.org/10.3390/ijms25052990.

Full text

Abstract:

The clinical benefits of using exogenous pulmonary surfactant (EPS) as a carrier of budesonide (BUD), a non-halogenated corticosteroid with a broad anti-inflammatory effect, have been established. Using various experimental techniques (differential scanning calorimetry DSC, small- and wide- angle X-ray scattering SAXS/WAXS, small- angle neutron scattering SANS, fluorescence spectroscopy, dynamic light scattering DLS, and zeta potential), we investigated the effect of BUD on the thermodynamics and structure of the clinically used EPS, Curosurf®. We show that BUD facilitates the Curosurf® phase

APA, Harvard, Vancouver, ISO, and other styles

47

Schousboe, Peter, Bülent Uslu, Amalie Schousboe, et al. "Lung Surfactant Deficiency in Severe Respiratory Failure: A Potential Biomarker for Clinical Assessment." Diagnostics 15, no. 7 (2025): 847. https://doi.org/10.3390/diagnostics15070847.

Full text

Abstract:

Background/Objectives: Critical lung infection affects alveolar cells and probably also their ability to perform surfactant procedures, but bedside tools for monitoring lung surfactants are lacking. In this descriptive exploratory study, we aimed to evaluate lung surfactant levels in bronchial aspirate (BA) from patients admitted to the intensive care unit due to severe respiratory failure. Methods: Bronchial aspirates were collected from nine patients (median age: 72 years, range: 52–85) who required orotracheal intubation. Samples were obtained within 24 h of mechanical ventilation initiatio

APA, Harvard, Vancouver, ISO, and other styles

48

Holm, B. A., and R. H. Notter. "Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity." Journal of Applied Physiology 63, no. 4 (1987): 1434–42. http://dx.doi.org/10.1152/jappl.1987.63.4.1434.

Full text

Abstract:

These experiments characterize the effects of hemoglobin and erythrocyte membrane lipids on the dynamic surface activity and adsorption facility of whole lung surfactant (LS) and a calf lung surfactant extract (CLSE) used clinically in surfactant replacement therapy for the neonatal respiratory distress syndrome (RDS). The results show that, at concentrations from 25 to 200 mg/ml, hemoglobin (Hb) increased the minimum dynamic surface tension of LS or CLSE mixtures (0.5 and 1.0 mumol/ml) from less than 1 to 25 dyn/cm on an oscillating bubble apparatus at 37 degrees C. Similarly, erythrocyte mem

APA, Harvard, Vancouver, ISO, and other styles

49

MIKOLKA, P., P. KOSUTOVA, M. KOLOMAZNIK, et al. "Efficacy of Surfactant Therapy of ARDS Induced by Hydrochloric Acid Aspiration Followed by Ventilator-Induced Lung Injury – an Animal Study." Physiological Research 71, Suppl. 2 (2022): S237—S249. http://dx.doi.org/10.33549/physiolres.935003.

Full text

Abstract:

The development of acute respiratory distress syndrome (ARDS) is known to be independently attributable to aspiration-induced lung injury. Mechanical ventilation as a high pressure/volume support to maintain sufficient oxygenation of a patient could initiate ventilator-induced lung injury (VILI) and thus contribute to lung damage. Although these phenomena are rare in the clinic, they could serve as the severe experimental model of alveolar-capillary membrane deterioration. Lung collapse, diffuse inflammation, alveolar epithelial and endothelial damage, leakage of fluid into the alveoli, and su

APA, Harvard, Vancouver, ISO, and other styles

50

MIKOLKA, P., P. KOSUTOVA, M. KOLOMAZNIK, et al. "Efficacy of Surfactant Therapy of ARDS Induced by Hydrochloric Acid Aspiration Followed by Ventilator-Induced Lung Injury – an Animal Study." Physiological Research 71, Suppl. 2 (2022): S237—S249. http://dx.doi.org/10.33549//physiolres.935003.

Full text

Abstract:

The development of acute respiratory distress syndrome (ARDS) is known to be independently attributable to aspiration-induced lung injury. Mechanical ventilation as a high pressure/volume support to maintain sufficient oxygenation of a patient could initiate ventilator-induced lung injury (VILI) and thus contribute to lung damage. Although these phenomena are rare in the clinic, they could serve as the severe experimental model of alveolar-capillary membrane deterioration. Lung collapse, diffuse inflammation, alveolar epithelial and endothelial damage, leakage of fluid into the alveoli, and su

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!